Your browser is no longer supported. Please, upgrade your browser.
Settings
BPMC Blueprint Medicines Corporation daily Stock Chart
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E- EPS (ttm)-5.39 Insider Own0.10% Shs Outstand47.41M Perf Week-8.35%
Market Cap3.73B Forward P/E- EPS next Y-7.70 Insider Trans-59.56% Shs Float42.92M Perf Month6.62%
Income-236.60M PEG- EPS next Q-1.90 Inst Own- Short Float6.09% Perf Quarter51.26%
Sales44.50M P/S83.72 EPS this Y-37.60% Inst Trans1.98% Short Ratio7.01 Perf Half Y9.72%
Book/sh9.52 P/B8.25 EPS next Y4.60% ROA-38.20% Target Price100.29 Perf Year-21.90%
Cash/sh10.42 P/C7.54 EPS next 5Y34.00% ROE-46.60% 52W Range44.58 - 103.12 Perf YTD45.76%
Dividend- P/FCF- EPS past 5Y-42.40% ROI-59.00% 52W High-23.80% Beta1.60
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low76.28% ATR3.48
Employees217 Current Ratio8.30 Sales Q/Q-37.50% Oper. Margin- RSI (14)47.23 Volatility4.91% 4.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.00% Profit Margin- Rel Volume1.45 Prev Close84.47
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 BMO Payout- Avg Volume372.85K Price78.58
Recom1.40 SMA20-4.32% SMA504.58% SMA20016.07% Volume542,387 Change-6.97%
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Sep-29-17Initiated BTIG Research Buy $90
Apr-05-17Reiterated Wedbush Outperform $43 → $50
Mar-13-17Upgrade Goldman Neutral → Buy
Feb-15-17Initiated Morgan Stanley Overweight
Dec-14-16Initiated Jefferies Buy $40
May-27-16Initiated Raymond James Outperform $23
May-26-15Initiated Wedbush Outperform
May-26-15Initiated JMP Securities Mkt Outperform $54
May-26-15Initiated Goldman Neutral $26
Mar-23-19 12:14PM  3 Cancer Treatment Stocks to Buy in March Motley Fool
Mar-05-19 08:01AM  Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference PR Newswire
Mar-01-19 07:10AM  Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +5.37%
06:52AM  Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-26-19 01:16PM  Blueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Feb-21-19 04:00PM  3 Top Healthcare Stocks to Buy in February Motley Fool
Feb-19-19 08:00AM  Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 PR Newswire
Feb-13-19 10:31AM  Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline Zacks
Feb-07-19 04:01PM  Blueprint Medicines to Present at Upcoming Investor Conferences in February PR Newswire
Jan-24-19 09:00AM  Three Companies Using AI and Innovation to Lead Healthcare Sector ACCESSWIRE
Jan-22-19 04:40PM  Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-07-19 03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +14.14%
03:06PM  Cancer stocks heat up after third big merger in the past month MarketWatch
Jan-04-19 08:00AM  Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals PR Newswire +9.82%
Dec-17-18 07:20AM  Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-08-18 11:33AM  Is Blueprint Medicines Corporation (BPMC) A Good Stock To Buy? Insider Monkey
Dec-04-18 12:14PM  Is Blueprint Medicines Corporations (NASDAQ:BPMC) CEO Overpaid Relative To Its Peers? Simply Wall St.
Dec-02-18 12:30PM  Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis PR Newswire
Nov-15-18 07:00AM  Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy PR Newswire -6.98%
Nov-05-18 07:40AM  Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-30-18 08:50AM  Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:44AM  Blueprint Medicines: 3Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports Third Quarter 2018 Financial Results PR Newswire
Oct-29-18 04:01PM  Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International PR Newswire -5.82%
Oct-23-18 04:01PM  Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018 PR Newswire
10:32AM  Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For Zacks
Oct-08-18 08:20AM  Report: Exploring Fundamental Drivers Behind Masonite International, Chart Industries, Blueprint Medicines, Cross Country Healthcare, HNI, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-06-18 08:50AM  Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers PR Newswire
Oct-01-18 08:00AM  Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva PR Newswire -5.34%
Sep-26-18 08:00AM  Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion PR Newswire
Sep-24-18 08:00AM  Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings PR Newswire
Sep-05-18 08:00AM  Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference PR Newswire
Aug-03-18 09:20AM  Edited Transcript of BPMC earnings conference call or presentation 1-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 06:31AM  What Blueprint Medicines Just Said About Its Future Motley Fool +5.11%
Aug-01-18 04:01PM  Blueprint Medicines to Present at Upcoming Investor Conferences in August PR Newswire +12.18%
08:35AM  Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34AM  Blueprint Medicines: 2Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports Second Quarter 2018 Financial Results PR Newswire
06:30AM  Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE
Jul-25-18 08:00AM  Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018 PR Newswire
Jun-21-18 08:30AM  New Research: Key Drivers of Growth for Illinois Tool Works, Aircastle, TriState Capital, Blueprint Medicines, MGE Energy, and Cubic Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
08:00AM  Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors PR Newswire
Jun-15-18 08:00AM  Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity PR Newswire -7.29%
Jun-06-18 07:40AM  Blog Exposure - Blueprint Medicines Signed Collaboration Deal with CStone Pharma to Develop and Commercialize Avapritinib, BLU-554, and BLU-667 in Greater China ACCESSWIRE -5.23%
Jun-04-18 04:23PM  Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today Motley Fool -9.24%
02:06PM  Blueprint Medicines CEO on genetic targeting for cancer CNBC Videos
07:00AM  Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China PR Newswire
Jun-02-18 10:17AM  Loxo Scores A Success With Second Targeted Cancer Drug Forbes
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos
May-31-18 06:01PM  The Big Thing to Watch at ASCO 2018 Motley Fool
08:30AM  Free Technical Insights on CASI Pharma and Three Other Biotech Stocks ACCESSWIRE
08:00AM  Blueprint Medicines to Present at Upcoming Investor Conferences in June PR Newswire
May-25-18 03:00AM  Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating Investor's Business Daily
May-24-18 12:41PM  Blueprint CEO traces biotech's rapid growth at opening of new HQ American City Business Journals
May-17-18 09:00AM  Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis PR Newswire -5.19%
May-07-18 11:55PM  Edited Transcript of BPMC earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-02-18 08:24AM  Blueprint Medicines: 1Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports First Quarter 2018 Financial Results PR Newswire
06:30AM  Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE
May-01-18 10:34AM  All You Need To Know About Blueprint Medicines Corporations (NASDAQ:BPMC) Financial Health Simply Wall St.
07:55AM  Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-25-18 08:00AM  Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018 PR Newswire
Apr-24-18 08:27AM  How Blueprint Medicines Got The Blues Forbes
Apr-16-18 12:29PM  Here's Why Blueprint Medicines Fell as Much as 15.1% Today Motley Fool -12.64%
Apr-15-18 09:30AM  Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors PR Newswire
Mar-19-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Government Properties Income Trust, Grand Canyon Education, The Chefs' Warehouse, Hemispherx BioPharma, Revlon, and Blueprint Medicines Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-14-18 04:35PM  Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 PR Newswire
Mar-06-18 08:00AM  Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference PR Newswire
Feb-28-18 07:00AM  Wired News ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF ACCESSWIRE
Feb-22-18 12:16AM  Edited Transcript of BPMC earnings conference call or presentation 21-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-21-18 11:38AM  Was Blueprint Medicines Corporations (NASDAQ:BPMC) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St. +6.90%
07:31AM  Blueprint Medicines reports 4Q loss Associated Press
07:01AM  Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
06:30AM  Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE
Feb-14-18 08:00AM  Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018 PR Newswire +6.35%
Jan-09-18 08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Barrett Business Services, Tech Data, Approach Resources, ICF International, Blueprint Medicines, and Government Properties Income Trust New Research Emphasizes Economic Growth GlobeNewswire
08:05AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit +6.10%
Dec-15-17 04:01PM  Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock PR Newswire
Dec-13-17 12:53PM  ETFs with exposure to Blueprint Medicines Corp. : December 13, 2017 Capital Cube
Dec-12-17 10:49PM  Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock PR Newswire -7.18%
03:08PM  Goldman Hopes Biotech Investors Keep Singing About These Blues Bloomberg
10:47AM  Company News For Dec 12, 2017 Zacks
Dec-11-17 04:31PM  Biotech Stocks Soar On Trial Data At Hematology Conference Investor's Business Daily +22.91%
04:01PM  Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock PR Newswire
10:25AM  Blueprint Medicines Wins Big in Early-Stage Trial 24/7 Wall St.
10:18AM  What does Blueprint Medicines Corporations (BPMC) Balance Sheet Tell Us Abouts Its Future? Simply Wall St.
09:40AM  Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers TheStreet.com
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
08:00AM  Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity PR Newswire
Dec-08-17 08:02AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit
Dec-07-17 02:50PM  Blueprint Medicines Corp. Value Analysis (NASDAQ:BPMC) : December 7, 2017 Capital Cube +6.25%
Dec-06-17 07:45AM  Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : December 6, 2017 Capital Cube
Nov-30-17 08:03AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit +6.38%
06:50AM  Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire
Nov-29-17 11:15AM  ETFs with exposure to Blueprint Medicines Corp. : November 29, 2017 Capital Cube
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit
Nov-15-17 08:07AM  See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurley ArielPrincipal Accounting OfficerMar 15Option Exercise1.87415776415Mar 19 05:23 PM
Albers Jeffrey W.CEO and PresidentMar 15Option Exercise1.8720,00037,40048,961Mar 19 05:25 PM
Hurley ArielPrincipal Accounting OfficerMar 15Sale85.5541535,5030Mar 19 05:23 PM
Albers Jeffrey W.CEO and PresidentMar 15Sale86.3920,0001,727,88428,961Mar 19 05:25 PM
Dorsch MarionChief Scientific OfficerMar 04Option Exercise37.112,30085,3532,300Mar 06 05:04 PM
Dorsch MarionChief Scientific OfficerMar 04Sale84.662,300194,7230Mar 06 05:04 PM
Haviland KateChief Operating OfficerMar 01Option Exercise23.1321,644500,63927,518Mar 05 05:31 PM
Haviland KateChief Operating OfficerMar 01Sale85.0521,6441,840,8225,874Mar 05 05:31 PM
Albers Jeffrey W.CEO and PresidentNov 19Option Exercise1.8728,96154,15728,961Nov 21 07:20 AM
Albers Jeffrey W.CEO and PresidentNov 05Option Exercise1.8720,00037,40020,000Nov 07 04:25 PM
Albers Jeffrey W.CEO and PresidentNov 05Sale63.4920,0001,269,7090Nov 07 04:25 PM
Dorsch MarionChief Scientific OfficerSep 17Option Exercise37.112,30085,3532,300Sep 19 04:08 PM
Dorsch MarionChief Scientific OfficerSep 17Sale70.472,300162,0920Sep 19 04:08 PM
Albers Jeffrey W.CEO and PresidentAug 06Option Exercise1.8720,00037,40020,000Aug 08 04:08 PM
Albers Jeffrey W.CEO and PresidentAug 06Sale70.5920,0001,411,8960Aug 08 04:08 PM
Albers Jeffrey W.CEO and PresidentMay 07Option Exercise1.8720,00037,40020,000May 09 04:29 PM
Albers Jeffrey W.CEO and PresidentMay 07Sale78.9020,0001,578,0910May 09 04:29 PM